Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells again...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cells
Main Authors: Martini, Silvia, Figini, Mariangela, Croce, Aurora, Frigerio, Barbara, Pennati, Marzia, Gianni, Alessandro Massimo, De Marco, Cinzia, Daidone, Maria Grazia, Argueta, Christian, Landesman, Yosef, Zaffaroni, Nadia, Satta, Alessandro
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7599683/
https://ncbi.nlm.nih.gov/pubmed/33023194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9102231
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados